Skip to main content
. 2014 Jan 8;25(3):592–598. doi: 10.1093/annonc/mdt543

Figure 1.

Figure 1.

Kaplan–Meier estimates of progression-free survival based on (A) independent central review and (B) overall survival (intent-to-treat population). MTP, nonpegylated liposomal doxorubicin + trastuzumab + paclitaxel; TP, trastuzumab + paclitaxel; HR, hazard ratio.